CYMABAY THERAPEUTICS, INC. AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT
Exhibit 4.4
CYMABAY THERAPEUTICS, INC.
AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT
This Amendment No. 1 (the Amendment) to that certain Registration Rights Agreement, dated as of September 30, 2013 (the Agreement), is made as of October 30, 2013, by and among CymaBay Therapeutics, Inc., a Delaware corporation (the Company), and the undersigned Holders of at least fifty percent (50%) of the outstanding Registrable Securities. All capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement unless the context otherwise requires.
RECITALS
WHEREAS, the Company and the Holders desire to amend the Agreement as set forth below; and
WHEREAS, to amend the Agreement, Section 6(g) of the Agreement requires the written consent of the Company and the holders of at least fifty percent (50%) of the outstanding Registrable Securities.
AGREEMENT
NOW, THEREFORE, in consideration of the mutual promises, representations, warranties, covenants and conditions set forth in the Agreement and this Amendment, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby amend the Agreement as follows:
1. The defined term Filing Deadline is hereby amended and restated in its entirety to read as follows:
Filing Deadline means, with respect to the Registration Statement required to be filed pursuant to Section 2(a), the 30th calendar day following October 31, 2013 and, provided, however, that if the Filing Deadline falls on a Saturday, Sunday or other day that the Commission is closed for business, the Filing Deadline shall be extended to the next Business Day on which the Commission is open for business.
2. Section 6(g) of the Agreement is hereby amended and restated in its entirety to read as follows:
Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented unless the same shall be in writing and signed by the Company and Holders holding 50% of the then outstanding Registrable Securities, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and Holders holding 50% of the then outstanding Registrable Securities; provided however, that execution of a Joinder Agreement by additional Purchasers after the Agreement Date shall not be deemed to be an amendment to this Agreement. For the avoidance of doubt, any Purchaser pursuant to the Institutional Purchase Agreement may become a party to this Agreement by executed a Joinder Agreement on or before November 22, 2013, and be deemed a Purchaser and Holder for all purposes hereunder. If a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall be reduced pro rata among all Holders. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of Holders and that does not directly or
indirectly affect the rights of other Holders may be given by Holders of all of the Registrable Securities to which such waiver or consent relates; provided, however, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the first sentence of this Section 6(g).
3. The Agreement, as amended by this Amendment, shall remain in full force and effect.
4. This Amendment shall be governed by and construed under the laws of the State of New York as such laws are applied to agreements among New York residents entered into and performed entirely within the State of New York.
5. This Amendment may be executed simultaneously in multiple counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. Execution and delivery of this Amendment by exchange of facsimile copies bearing the facsimile signature of a party hereto shall constitute a valid and binding execution and delivery of this Amendment by such party. Such facsimile copies shall constitute enforceable original documents.
[Remainder of Page Intentionally Left Blank]
IN WITNESS WHEREOF, the parties have executed this Amendment No. 1 to Registration Rights Agreement as of the date first written above.
CymaBay Therapeutics, Inc. | ||
By: | /s/ Harold VanWart | |
Name: Harold Van Wart | ||
Title: Chief Executive Officer |
JOINDER AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the undersigned hereby acknowledges receipt of a true and complete copy of the Amendment No. 1 to Registration Rights Agreement, dated as of October 30, 2013, by and among CymaBay Therapeutics, Inc. and the Purchasers party thereto, and agrees to be bound by all of the provisions thereof.
IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the 30th day of October, 2013.
ALTA BIOPHARMA PARTNERS III, L.P. | ||||
By: Alta BioPharma Management III, LLC, | ||||
By: | /s/ Ed Penhoet | |||
Name: Ed Penhoet | ||||
Title: Director | ||||
ALTA BIOPHARMA PARTNERS III GMBH & CO. BETEILIGUNGS KG | ||||
By: Alta BioPharma Management III, LLC | ||||
By: | /s/ Ed Penhoet | |||
Name: Ed Penhoet | ||||
Title: Director | ||||
ALTA BIOPHARMA PARTNERS III, LLC | ||||
By: | /s/ Ed Penhoet | |||
Name: Ed Penhoet | ||||
Title: Director |
JOINDER AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the undersigned hereby acknowledges receipt of a true and complete copy of the Amendment No. 1 to Registration Rights Agreement, dated as of October 30, 2013, by and among CymaBay Therapeutics, Inc. and the Purchasers party thereto, and agrees to be bound by all of the provisions thereof.
IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the 30th day of October, 2013.
VERSANT VENTURE CAPITAL II, L.P. | ||||
By: Versant Ventures II, LLC | ||||
Its: General Partner | ||||
By: | /s/ Bradley J. Bolzon | |||
Name: Bradley J. Bolzon | ||||
Title: Managing Director | ||||
VERSANT SIDE FUND II, L.P. | ||||
By: Versant Ventures II, LLC | ||||
Its: General Partner | ||||
By: | /s/ Bradley J. Bolzon | |||
Name: Bradley J. Bolzon | ||||
Title: Managing Director | ||||
VERSANT AFFILIATES FUND II-A, L.P. | ||||
By: Versant Ventures II, LLC | ||||
Its: General Partner | ||||
By: | /s/ Bradley J. Bolzon | |||
Name: Bradley J. Bolzon | ||||
Title: Managing Director |
JOINDER AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the undersigned hereby acknowledges receipt of a true and complete copy of the Amendment No. 1 to Registration Rights Agreement, dated as of October 30, 2013, by and among CymaBay Therapeutics, Inc. and the Purchasers party thereto, and agrees to be bound by all of the provisions thereof.
IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the 30th day of October, 2013.
JOHNSON & JOHNSON DEVELOPMENT CORPORATION | ||
By: | /s/ Ashish K. Xavier |
Name: | Ashish K. Xavier |
Title: | VP, Venture Investments |
JOINDER AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the undersigned hereby acknowledges receipt of a true and complete copy of the Amendment No. 1 to Registration Rights Agreement, dated as of October 30, 2013, by and among CymaBay Therapeutics, Inc. and the Purchasers party thereto, and agrees to be bound by all of the provisions thereof.
IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the 30th day of October, 2013.
DEERFIELD SPECIAL SITUATIONS FUND, L.P. | ||
By: Deerfield MGMT, L.P. | ||
Its: General Partner | ||
By: J.E. Flynn Capital, LLC | ||
Its: General Partner | ||
By: | /s/ David J. Clark | |
Name: David J. Clark | ||
Title: Authorized Signatory | ||
DEERFIELD SPECIAL SITUATIONS MASTER FUND, L.P. | ||
By: Deerfield MGMT, L.P. | ||
Its: General Partner | ||
By: J.E. Flynn Capital, LLC | ||
Its: General Partner | ||
By: | /s/ David J. Clark | |
Name: David J. Clark | ||
Title: Authorized Signatory |
JOINDER AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the undersigned hereby acknowledges receipt of a true and complete copy of the Amendment No. 1 to Registration Rights Agreement, dated as of October 30, 2013, by and among CymaBay Therapeutics, Inc. and the Purchasers party thereto, and agrees to be bound by all of the provisions thereof.
IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the 30th day of October, 2013.
PICTET BIOTECH | ||
By: | /s/ Marie-Claude Lange | |
/s/ Alexandre Ris | ||
Name: Marie-Claude Lange/Alexandre Ris | ||
Title: Directors |
JOINDER AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the undersigned hereby acknowledges receipt of a true and complete copy of the Amendment No. 1 to Registration Rights Agreement, dated as of October 30, 2013, by and among CymaBay Therapeutics, Inc. and the Purchasers party thereto, and agrees to be bound by all of the provisions thereof.
IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the 30th day of October, 2013.
VENROCK PARTNERS, L.P. | ||
By: Venrock Partners Management, LLC | ||
Its: General Partner | ||
By: | /s/ Anthony B. Evnin | |
Name: Anthony B. Evnin | ||
Title: Member | ||
VENROCK ASSOCIATES IV, L.P. | ||
By: Venrock Management IV, LLC | ||
Its: General Partner | ||
By: | /s/ Anthony B. Evnin | |
Name: Anthony B. Evnin | ||
Title: Member | ||
VENROCK ENTREPRENEURS FUND IV, L.P. | ||
By: VEF Management IV, LLC | ||
Its: General Partner | ||
By: | /s/ Anthony B. Evnin | |
Name: Anthony B. Evnin | ||
Title: Member |
JOINDER AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the undersigned hereby acknowledges receipt of a true and complete copy of the Amendment No. 1 to Registration Rights Agreement, dated as of October 30, 2013, by and among CymaBay Therapeutics, Inc. and the Purchasers party thereto, and agrees to be bound by all of the provisions thereof.
IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the 30th day of October, 2013.
T. ROWE PRICE HEALTH SCIENCES FUND, INC. | ||||
By: T.Rowe Price Associates, Inc., | ||||
Investment Adviser | ||||
By: | /s/ Taymour Tamaddon | |||
Name: Taymour Tamaddon | ||||
Title: Vice President |
JOINDER AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the undersigned hereby acknowledges receipt of a true and complete copy of the Amendment No. 1 to Registration Rights Agreement, dated as of October 30, 2013, by and among CymaBay Therapeutics, Inc. and the Purchasers party thereto, and agrees to be bound by all of the provisions thereof.
IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the 30th day of October, 2013.
ALLIANCEBERNSTEIN VENTURE FUND I, L.P. | ||||
By: AllianceBernstein ESG Venture | ||||
Management, L.P., its General Partner | ||||
By: AllianceBernstein Global Derivatives | ||||
Corporation, its General Partner | ||||
By: | /s/ Troy Fukumoto | |||
Name: Troy Fukumoto | ||||
Title: Vice President |
JOINDER AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the undersigned hereby acknowledges receipt of a true and complete copy of the Amendment No. 1 to Registration Rights Agreement, dated as of October 30, 2013, by and among CymaBay Therapeutics, Inc. and the Purchasers party thereto, and agrees to be bound by all of the provisions thereof.
IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the 30th day of October, 2013.
NOVO A/S | ||||
By | /s/ Jack B. Nielsen | |||
Name: Jack B. Nielsen | ||||
Title: | Partner | |||
Novo Ventures | ||||
Tuborg Havnevej 19 | ||||
DK-2900 Hellerup |